It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NBIX’s FA Score shows that 0 FA rating(s) are green whileSNGX’s FA Score has 1 green FA rating(s), and WINT’s FA Score reflects 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NBIX’s TA Score shows that 5 TA indicator(s) are bullish while SNGX’s TA Score has 4 bullish TA indicator(s), and WINT’s TA Score reflects 4 bullish TA indicator(s).
NBIX (@Pharmaceuticals: Other) experienced а +1.92% price change this week, while SNGX (@Biotechnology) price change was +2.09% , and WINT (@Biotechnology) price fluctuated -1.13% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +72.11%. For the same industry, the average monthly price growth was +14.53%, and the average quarterly price growth was +64.76%.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.74%. For the same industry, the average monthly price growth was +2.75%, and the average quarterly price growth was +0.73%.
NBIX is expected to report earnings on Aug 05, 2025.
SNGX is expected to report earnings on May 09, 2025.
WINT is expected to report earnings on Apr 15, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Biotechnology (+5.74% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
NBIX | SNGX | WINT | |
Capitalization | 13.7B | 6.37M | 2.89M |
EBITDA | 358M | -8.06M | -9.36M |
Gain YTD | -8.425 | -27.644 | -95.477 |
P/E Ratio | 57.20 | N/A | 0.83 |
Revenue | 1.89B | 0 | 0 |
Total Cash | 1.03B | 9.84M | 917K |
Total Debt | 428M | 2.2M | 2.01M |
NBIX | SNGX | WINT | ||
---|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 60 | 2 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 72 Overvalued | 28 Undervalued | 57 Fair valued | |
PROFIT vs RISK RATING 1..100 | 76 | 100 | 100 | |
SMR RATING 1..100 | 60 | 96 | 97 | |
PRICE GROWTH RATING 1..100 | 47 | 86 | 97 | |
P/E GROWTH RATING 1..100 | 37 | 100 | 5 | |
SEASONALITY SCORE 1..100 | 50 | n/a | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNGX's Valuation (28) in the Biotechnology industry is in the same range as WINT (57) and is somewhat better than the same rating for NBIX (72). This means that SNGX's stock grew similarly to WINT’s and somewhat faster than NBIX’s over the last 12 months.
NBIX's Profit vs Risk Rating (76) in the Biotechnology industry is in the same range as SNGX (100) and is in the same range as WINT (100). This means that NBIX's stock grew similarly to SNGX’s and similarly to WINT’s over the last 12 months.
NBIX's SMR Rating (60) in the Biotechnology industry is somewhat better than the same rating for SNGX (96) and is somewhat better than the same rating for WINT (97). This means that NBIX's stock grew somewhat faster than SNGX’s and somewhat faster than WINT’s over the last 12 months.
NBIX's Price Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for SNGX (86) and is somewhat better than the same rating for WINT (97). This means that NBIX's stock grew somewhat faster than SNGX’s and somewhat faster than WINT’s over the last 12 months.
WINT's P/E Growth Rating (5) in the Biotechnology industry is in the same range as NBIX (37) and is significantly better than the same rating for SNGX (100). This means that WINT's stock grew similarly to NBIX’s and significantly faster than SNGX’s over the last 12 months.
NBIX | SNGX | WINT | |
---|---|---|---|
RSI ODDS (%) | 1 day ago74% | N/A | 1 day ago83% |
Stochastic ODDS (%) | 1 day ago62% | 1 day ago82% | 1 day ago77% |
Momentum ODDS (%) | 1 day ago69% | 1 day ago83% | 1 day ago74% |
MACD ODDS (%) | 1 day ago65% | 1 day ago73% | N/A |
TrendWeek ODDS (%) | 1 day ago70% | 1 day ago78% | 1 day ago90% |
TrendMonth ODDS (%) | 1 day ago70% | 1 day ago79% | 1 day ago90% |
Advances ODDS (%) | 1 day ago72% | 8 days ago77% | 8 days ago76% |
Declines ODDS (%) | 14 days ago62% | 6 days ago90% | 3 days ago90% |
BollingerBands ODDS (%) | 1 day ago77% | N/A | 1 day ago75% |
Aroon ODDS (%) | 1 day ago60% | 1 day ago90% | 1 day ago90% |
A.I.dvisor tells us that NBIX and LFCR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NBIX and LFCR's prices will move in lockstep.
Ticker / NAME | Correlation To NBIX | 1D Price Change % | ||
---|---|---|---|---|
NBIX | 100% | +0.35% | ||
LFCR - NBIX | 31% Poorly correlated | N/A | ||
EOLS - NBIX | 30% Poorly correlated | +8.38% | ||
CGC - NBIX | 29% Poorly correlated | N/A | ||
ELAN - NBIX | 27% Poorly correlated | +0.30% | ||
TLRY - NBIX | 26% Poorly correlated | -1.65% | ||
More |
A.I.dvisor indicates that over the last year, SNGX has been loosely correlated with THAR. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SNGX jumps, then THAR could also see price increases.
Ticker / NAME | Correlation To SNGX | 1D Price Change % | ||
---|---|---|---|---|
SNGX | 100% | +3.17% | ||
THAR - SNGX | 46% Loosely correlated | +5.42% | ||
VRAX - SNGX | 36% Loosely correlated | +2.04% | ||
QURE - SNGX | 36% Loosely correlated | +4.66% | ||
ATHA - SNGX | 31% Poorly correlated | +6.03% | ||
LGVN - SNGX | 30% Poorly correlated | -5.60% | ||
More |
A.I.dvisor indicates that over the last year, WINT has been loosely correlated with MLEC. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if WINT jumps, then MLEC could also see price increases.
Ticker / NAME | Correlation To WINT | 1D Price Change % | ||
---|---|---|---|---|
WINT | 100% | +5.36% | ||
MLEC - WINT | 49% Loosely correlated | +5.50% | ||
DVHGF - WINT | 37% Loosely correlated | N/A | ||
INMB - WINT | 31% Poorly correlated | +1.11% | ||
DYN - WINT | 29% Poorly correlated | +4.49% | ||
CDTX - WINT | 27% Poorly correlated | +2.80% | ||
More |